跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Philippines FDA
/
Gemcisaph-200
Approved
STANDARD
Gemcisaph-200
Bruck Pharma Private Limited
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
ff12d1ff03d4ae97
Company
Bruck Pharma Private Limited
Type
Standard
Approval Details
Approval Id
ff12d1ff03d4ae97
Drug Approval Philippines Name
Gemcisaph-200
Product Name
Gemcisaph-200
Registration Number
DRP-13075
Brand Name
Gemcisaph-200
Generic Name
Gemcitabine (As Hydrochloride)
Dosage Form
Lyophilized Powder for Injection (IV Infusion)
Dosage Strength
200 mg
Manufacturer
Bruck Pharma Private Limited
Importer
Nelpa Lifesciences, Inc.
Distributor
Nelpa Lifesciences, Inc.
Issuance Date
28 November 2022
Expiry Date
28 November 2027
Pharmacologic Category
Antineoplastic
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
ff12d1ff03d4ae97
Type
Standard
Back to Philippines FDA Approvals